GlassScriptPhysician profile
Kristy Carter
NPI 1487942421
$3,863.33
in general payments reported to CMS, 2019-2025
19 companies · $754 in 2025
The $754 reported for 2025 was more than what 75% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $510 · 2022: $756 · 2023: $826 · 2024: $1,017 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,597.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $651.46 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $549.89 | 2021-2025 | Qelbree, Qelbree |
| Abbvie INC. | $544.65 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $462.19 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $440.63 | 2021-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $319.01 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $255.76 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $126.29 | 2024-2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $123.27 | 2021-2024 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.63 | 2022-2025 | Caplyta |
| Lilly USA, LLC | $68.55 | 2024-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $60.21 | 2022-2023 | Trintellix |
| Neurocrine Biosciences, INC. | $49.49 | 2022-2024 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $35.86 | 2021-2022 | |
| Edwards Lifesciences Corporation | $30.68 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $19.76 | 2024 | Pancreaze |
| Novo Nordisk INC | $18.46 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.50 | 2024 | |
| Exact Sciences Corporation | $13.04 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristy Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.